长春高新: 关于公司股票交易异常波动的公告

Group 1 - The company's A-share stock experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20.00% over two consecutive trading days on September 1 and 2, 2025 [1] - The company confirmed that the market is highly focused on its 2025 semi-annual performance, innovative drug business, and the proposed issuance of overseas listed foreign shares (H-shares) for listing on the Hong Kong Stock Exchange [1][2] - The net profit attributable to shareholders for the first half of 2025 was 983 million yuan, a decrease of 42.85% compared to the same period last year [1] Group 2 - The company has introduced its innovative drug Jinbeixin (Fuxin Qibai monoclonal antibody) and other key research projects, highlighting the long cycle, high investment, and uncertainty associated with innovative drug development [2] - The proposal for issuing H-shares and applying for listing on the main board of the Hong Kong Stock Exchange is currently progressing in an orderly manner [2] - The board confirmed that there are no undisclosed significant matters that should be disclosed according to the Shenzhen Stock Exchange's listing rules [2]